Abstract • 87

This study about use of Ribomunyl in recurrent inflammatory ENT and respiratory diseases in children includes 739 patients from 39 centers. Age spectrum of patients varied within 1-12 years, with higher frequency in category of 3-5 years. Ribomunyl was used for various diagnosis, most often in rhinopharyngitis and bronchitis. Percentage of children is given from the file of patients suffering from asthma and allergy. Children with at least 5 episodes of recurrent disease in the last 6 months were added to the study. Episodes treated with antibiotics, days spent in home care, in bed and days with fever were recorded. The study evaluates all criteria before treatment and after 3- and 6-months of treatment. Decreased number (2.5 times) and duration (2.7 times) of disease episodes, good compliance of drugs and a significant reduction (3.6 times) in treatment with antibiotics are the main advantages of ribosomal immunotherapy.